A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen.
作者信息
Doshi J C, Vaidya A B, Antarkar D S, Deolalikar R, Antani D H
机构信息
Dr Balabhai Nanavati Hospital and Research Center, Juhu, Bombay.
出版信息
Indian J Gastroenterol. 1994 Jan;13(1):7-8.
BACKGROUND
There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders.
AIM
To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers.
METHODS
Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks.
RESULTS
None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation.
CONCLUSION
Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.
Zotero 插件